Antipsychotic Use Pattern in Schizophrenia Outpatients: Correlates of Polypharmacy
Esra Yazici1, *, Ali S. Cilli1, Ahmet B. Yazici1, Hayriye Baysan1, Mustafa Ince2, Sukriye Bosgelmez2, Serkan Bilgic1, Betul Aslan1, Atila Erol1
Identifiers and Pagination:Year: 2017
First Page: 92
Last Page: 103
Publisher ID: CPEMH-13-92
Article History:Received Date: 07/12/2016
Revision Received Date: 24/05/2017
Acceptance Date: 22/06/2017
Electronic publication date: 11/08/2017
Collection year: 2017
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
This study investigates the antipsychotic use patterns of patients with schizophrenia and its correlations in their daily drug use patterns.
Patients with schizophrenia who have regular records at two different community counselling centres (CCS) were included in the study. Information about their medications and sociodemographic data was recorded through face-to-face interviews and supporting information about their drug use patterns was obtained from their relatives/caregivers/nurse. The Clinical Global Impression Scale (severity of illness) and the General Assessment of Functionality scales were also administered.
Patients with schizophrenia used 2.0 ± 0.81 antipsychotics daily and 3.52 ± 2.55 pills (1–18). Seventy-one percent of the patients used two or more kinds of psychotropic drugs. The most frequently used antipsychotics were quetiapine, a second generation antipsychotic, and haloperidol, a typical antipsychotic. Clinical severity, regular visits to a CCS and use of depot antipsychotics were independent predictors for polypharmacy.
The rate of polypharmacy use is high in Turkey. There are multiple risk factors related with polipharmacy. New studies should focus risk factors for preventing polypharmacy.